title: Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
abstract: This review outlines the evolving role of percutaneous coronary intervention (PCI) for stable angina in the context of the widely discussed Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) and Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trials. Factors outlined include defining the appropriate patient population, the clinical circumstances, and the technical aspects of the procedure to optimize clinical outcomes and minimize risk. The COURAGE Trial, as others reported earlier, reported no difference in death or myocardial infarction with PCI compared with medical therapy for stable angina. In patients with type 2 diabetes mellitus in the BARI 2D Trial, a strategy of revascularization with coronary artery bypass graft surgery (CABG) or PCI resulted in no difference in mortality compared with optimal medical therapy. However, PCI for stable angina was associated with reduced angina and improved quality of life. Procedural aspects of PCI that support its continuing role in the management of patients with stable angina include the frequent advancements in PCI technology that have further enhanced both acute and long-term success. In conclusion, the implications of these findings for clinical practice include evaluating the use of PCI for stable angina in addition to optimal medical therapy to reduce angina and improve quality of life, but individualizing care for higher risk patients with more complex coronary artery disease who were not enrolled in the COURAGE and BARI 2D trials.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, 75390-8837, USA. elizabeth.holper@utsouthwestern.edu
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Holper
authors.forename: Tayo
authors.initials: T
authors.lastname: Addo
mesh_terms: D000787:Angina Pectoris / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D017130:Angioplasty; D002317:Cardiovascular Agents / Q000627:therapeutic use; D019090:Case Management; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology*; D006801:Humans; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents